Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by dcoadtradeson Oct 15, 2018 2:52pm

275 Views

Post# 28804012

RE:KALY and GWPH - nice comparison

Those comparisons are making me giddy :)

I might be wrong, but my understanding was TBP (Tetra Bio Pharma) got the nod from the FDA to begin clinical trials for their CBD cancer associated drug. They're following all the correct paths Kaly is. I was going to look into being a buyer, but then realized they would need to come up with a bunch of cash to fund trials , and will probaby do a PP and have long periods of staggered dillution to follow. One to watch though.

Bullboard Posts

Visionstate set to leverage success in the U.S. market